Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

Core Points - Renalytix plc has submitted a hearing request to the Nasdaq Hearings Panel, which has stayed the suspension of the Company's securities pending the Panel's decision [1][2] - The Company intends to present a strategic plan to regain compliance with Nasdaq listing requirements during the hearing [1] - The Company has been notified of non-compliance with Nasdaq's minimum closing bid price and market value requirements [2] Company Information - Renalytix plc is an AI-enabled in-vitro diagnostics and laboratory services company, recognized for its kidney health prognostic test, kidneyintelX.dkd [3] - The kidneyintelX.dkd test is the first FDA-authorized prognostic test for early-stage chronic kidney disease risk assessment in type 2 diabetes patients [3]